Report Overview

The global transplant diagnostic market was pegged at US$ 1 billion in 2021 and is expected to witness a CAGR of 8% during the forecast period. 

Market Fundamental 

Diagnostic work that is typically done before to and after transplants is referred to as "transplant diagnostics." It aids in the analysis of the patient's medical circumstances. If HAIs are not prevented, the person with low immunity bears the chance of contracting them, which could be fatal. Healthcare professionals and laboratory experts work together in harmony during the operation to ensure better patient results.

When an organ such as the liver, pancreas, lungs, kidney, or heart fails, it may be necessary to transplant it. The antigens on the surface of human leukocytes control body recognition and prevent the body from rejecting transplants of alien tissue. The genes on chromosome six regulate a complex known as the major histocompatibility complex in humans. In organ and bone marrow transplants, diagnostic human leukocyte antigen (HLA) testing is carried out to ascertain the tissue compatibility between the donor and recipient.

[88643224]

Market Dynamics 

A few of the key factors propelling the expansion of the global Transplant Diagnostics Market are the increase in stem cell-based, soft tissue, and solid transplantation, rising geriatric population, rising prevalence of persistent diseases, augmentation in laboratory automation of diagnostic operations assisted by robots, and technological advancements in human leukocyte antigen typing. Additionally, a rise in public and private investments in the development of novel human leukocyte antigen (HLA) products for testing, the exponential growth of HLA diagnostic applications, improvements in healthcare infrastructure, particularly in developing countries, a steady decline in the average cost of gene sequencing, and expanding NGS and PCR instrument installation bases are all contributing to the growth of the global transplant diagnostics market.

Market Ecosystem 

The global transplant diagnostics market has been analysed from five perspectives by technology, product, transplant type, application and region. 

Transplant Diagnostics Market by Technology

Based on technology, the global transplant diagnostics market has been segmented into molecular and non-molecular. The molecular is sub-segmented into PCR based molecular assay and sequencing based molecular assay. The molecular segment dominated the market during forecast period. Medical professionals choose molecular assays over non-molecular testing. Additionally, due to its advantages like accuracy, efficacy, and decreased risk, HLA typing has gradually surpassed serological assays in popularity. Due to its many uses, the PCR-based test sector now has the largest market share.

Transplant Diagnostics Market by Product

[1231923]

Based on product, the transplant diagnostics market has been segmented into instrument, software, and reagent. The instruments for transplant diagnostics are products developed to expedite and enhance the efficacy of transplant diagnostics. Non-molecular test and molecular assay methods are utilised in transplant diagnostics for a variety of organ transplants, including kidney, liver, heart, lung, and pancreatic. The transplant types covered include solid organ and stem cell transplants, which are employed by commercial service providers, hospitals, research labs, and transplant centres.

Transplant Diagnostics Market by Transplant Type

Based on transplant type, the transplant diagnostics market has been segmented into solid organ, stem cell, soft tissue. The solid organ transplant segment dominated the segment during forecast period. A well-established and useful therapy option for patients with end-stage organ dysfunction, organ transplantation was first introduced as an experimental procedure in the 20th century. The kidney and liver are the two organs that receive the most transplants. Additionally, in February 2022, the Health Resources and Services Administration reported that there were over 106,000 persons on the national transplant waiting list in the United States for solid organ transplants. The kidney (83%) is the organ with the highest waiting time, followed by the liver (11%), pancreas (1%), heart (3%), and others (2%). Increased testing is required for transplantation due to the increase in demand for solid organs, which is anticipated to propel the segment's growth during the forecast period.

Transplant Diagnostics Market by Application 

Based on application, the transplant diagnostics market has been segmented into diagnostics and research. The diagnostics segment dominated the market during forecast period due to government initiates and rising research and development in the field of molecular diagnostics 

Transplant Diagnostics Market by Region

Based on region, the transplant diagnostics market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. The highest revenue portion came from North America. Major influences include the widespread use of cutting-edge methods and diagnostic technologies, rising healthcare costs, and the accessibility of qualified personnel. Due to factors including a highly established healthcare infrastructure and the availability of qualified specialists, the U.S. has the biggest market share. Additionally, the widespread use of stem cell therapies, tailored pharmaceuticals, and soft tissue transplants is promoting regional market expansion.

Competitive Landscape 

Some of the prominent players in the global transplant diagnostics market include 

• Thermo Fisher Scientific, Inc.
• Linkage Biosciences
• Illumina, Inc.
• F. Hoffmann La-Roche AG.
• Abbott Laboratories, Inc.
• Qiagen N.V.
• Sigma-Aldrich, 
• Immucor Transplant Diagnostics, Inc.
• Biomérieux SA, 
• Bio-rad Laboratories, Inc.
• Affymetrix, Inc.
• Omixon Ltd.

Strategic Development 

• In March 2022, Immucor, Inc., a company that specialises in transfusion and transplantation diagnostics, recently announced the addition of two new products to its portfolio of transplant diagnostics, proving its continued dedication to new developments in the histocompatibility sector.
• In March 2022, HepatoPredict, a predictive gene expression signature test to determine whether patients may benefit from liver transplantation, was developed in collaboration between Biocartis and Ophiomics.
• In December 2020, Thermo Fisher Scientific, a leading global provider of scientific services, announced that it would expand its presence in the North American and European continents for the development of sterile pharma products and the commercial manufacture of essential drugs, vaccines, and therapies.

Frequently Asked Questions About This Report